Jesse’s Journey Becomes Defeat Duchenne Canada
New Name – Same Mission: Jesse’s Journey Becomes Defeat Duchenne Canada
Jesse’s Journey, Canada’s only national charity dedicated to ending the most common and most fatal form of muscular dystrophy has become Defeat Duchenne Canada. The London-based organization has united families, raised awareness and funded almost $15 million in research projects around the world. After more than 30 years under the banner of Jesse’s Journey, Canada’s leading fundraiser for Duchenne muscular dystrophy has partnered with its vibrant community members to choose a new name that reflects their nationwide impact.
Read the full press release from Defeat Duchenne Canada here.
About Defeat Duchenne Canada
Defeat Duchenne Canada is the country’s only national charity dedicated to ending Duchenne muscular dystrophy.
Their goal is to provide leadership in research, advocacy and support to ensure our boys can live long and active lives.
The NMD4C are excited to continue our partnership with Defeat Duchenne Canada, and are grateful to have the opportunity to work together to raise the standards of care for NMDs and access to therapies across Canada.
Check out the three-part Defeat Duchenne Canadian Conference Series addressing Duchenne Muscular Dystrophy Standards of Care in Canada, hosted in 2021 by Defeat Duchenne Canada in collaboration with MDC and the NMD4C.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.